AI Summary
The EMA safety committee is advising restrictions on the use of topiramate in young women due to potential neurodevelopmental disorders in their children when taken during pregnancy. Summary unavailable.
The EMA safety committee recommends new measures to limit topiramate use in young women based on recent data suggesting more neurodevelopmental disorders for offspring when it’s used during pregnancy.
Medscape Medical News